Analizziamo Incyte Corp. (INCY) sul grafico giornaliero
Il trend di Incyte Corp. è rialzista dal 25 novembre 2011, sul grafico daily, il titolo è in lieve Buy, ma l’ alligator si sta contorcendo, indicandoci di stare attenti a dei livelli che potrebbero interrompere il trend in atto. Il titolo resta rialzista fino...Leggi di piùDuring the first quarter, the Company shipped $25.1 million of Jakafi to its specialty pharmacies.
The Company currently uses the sell-through method for product revenue recognition, which means revenue is deferred until the specialty pharmacy ships product to the patient. For the first quarter of 2012, $21.2 million of product was delivered to patients and recognized as gross revenue. The gross to net adjustment for product revenue recognized was approximately $1.9 million, resulting in net product revenue of $19.3 million for the first quarter.
The Company’s cumulative net product deferred revenue as of March 31, 2012, was $6.0 million.